AbCellera partners with Gilead on antibodies for infectious disease

14 June 2019

Privately-held Canadian biotech AbCellera has announced a newly-minted deal with US biotech major Gilead Sciences (Nasdaq: GILD). The collaboration will focus on discovering ultra-rare antibodies with certain defined properties for the treatment of an array of infectious diseases.

Gilead has specifically chosen AbCellera for this venture due to the company’s proven screening technologies and expertise in finding ‘needles in the haystack’ – antibodies that exist in very low abundance making them difficult to single out from natural immune sources and hence have eluded traditional legacy technologies.

AbCellera will apply its expertise in single-cell screening of natural immune sources to generate rich panels of antibody candidates for evaluation by Gilead.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK